Crizanlizumab in sickle cell disease

Kenneth I. Ataga; Abdullah Kutlar; Julie Kanter

doi:10.1056/NEJMc1703162

Crizanlizumab in sickle cell disease

Kenneth I. Ataga, Abdullah Kutlar, Julie Kanter

Pulmonary Disease

Research output: Contribution to journal › Letter › peer-review

57 Scopus citations

Original language	English (US)
Pages (from-to)	1795-1796
Number of pages	2
Journal	New England Journal of Medicine
Volume	376
Issue number	18
DOIs	https://doi.org/10.1056/NEJMc1703162
State	Published - May 4 2017

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1056/NEJMc1703162

Cite this

@article{b16da949eb6f4489810809d66b7c02fa,

title = "Crizanlizumab in sickle cell disease",

author = "Ataga, {Kenneth I.} and Abdullah Kutlar and Julie Kanter",

year = "2017",

month = may,

day = "4",

doi = "10.1056/NEJMc1703162",

language = "English (US)",

volume = "376",

pages = "1795--1796",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "18",

}

TY - JOUR

T1 - Crizanlizumab in sickle cell disease

AU - Ataga, Kenneth I.

AU - Kutlar, Abdullah

AU - Kanter, Julie

PY - 2017/5/4

Y1 - 2017/5/4

UR - http://www.scopus.com/inward/record.url?scp=85044534502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044534502&partnerID=8YFLogxK

U2 - 10.1056/NEJMc1703162

DO - 10.1056/NEJMc1703162

M3 - Letter

C2 - 28467874

AN - SCOPUS:85044534502

SN - 0028-4793

VL - 376

SP - 1795

EP - 1796

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 18

ER -

Crizanlizumab in sickle cell disease

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this